Diagnostic and prognostic values of anti‐helicobacter pylori antibody combined with serum CA724, CA19‐9, and CEA for young patients with early gastric cancer

Abstract

Background

To investigate the value of anti‐helicobacter pylori (Hp) antibody, serum carbohydrate antigen (CA)‐724, CA19‐9, and carcinoembryonic antigen (CEA) in the diagnosis and prognosis evaluation of young patients with early gastric cancer.

Methods

A total of 200 young patients with gastric cancer from April 2014 to December 2015 were enrolled. A total of 206 patients with gastritis and 204 healthy subjects were also selected. Gastric cancer patients were followed up for 3 years, and the number of recurrences, metastasis, and death was recorded.

Results

The positive rate of anti‐Hp antibody, CA724, CA19‐9, and CEA in young patients with early gastric cancer were significantly higher than those in gastritis and healthy subjects ( P < .05), and was positively correlated with tumor stage, tumor size, and lymph node metastasis ( P < .05). The predicting model was as follows: Logit ( P) = 26.433‐3.014(CA724)‐3.908(CA19‐9)‐0.303(CEA)‐2.208(anti‐Hp antibody, Positive = 1; Negative = 0). This model had a high value in identifying young patients with early gastric cancer with AUC of 0.918, and the estimated probability was .806. Compared to patients with negative anti‐Hp antibody and low serum levels of CA724, CA19‐9, and CEA, the recurrence rate, metastasis rate, and mortality of patients with positive anti‐Hp antibody, high serum levels of CA724, CA19‐9, and CEA increased significantly ( P < .05).

Conclusion

This study indicated that anti‐Hp antibody combined with CA724, CA19‐9, and CEA had important value in the identification of young patients with early gastric cancer and were of great value in evaluating the risk of postoperative recurrence, metastasis, and death.